CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, A B-Cell Maturation Antigen Directed Chimeric Antigen Receptor T cell Therapy, in Relapsed/Refractory Multiple Myeloma.

Preliminary results indicate  that anti-BCMA CAR-T cell therapy, ciltacabtagene autleucel (cilta-cel), resulted in early, deep and durable responses in heavily pre-treated patients with MM.   ORR was , sCR .  Durability of response at data cut-off was Additional studies in MM are ongoing.